Total Voting Rights

Genflow Biosciences PLC

30 October 2026

 

30 October 2026

Genflow Biosciences plc

(“Genflow” or the “Company”)

Total Voting Rights

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 30 October 2026 consists of 594,534,781 ordinary shares of £0.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 594,534,781.

The figure of 594,534,781 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. 

Contacts

Genflow Biosciences Plc	https://genflowbio.com
Dr Eric Leire, Chief Executive Officer	[phone]
ON365 Partners Inc.	[phone]
Eric Laub, Investor Relations	www.on365ptrs.com

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is a persistent unmet medical need. Genflow is also advancing an ophthalmology program, GF-1006, an mRNA-based SIRT6 therapy targeting corneal pathologies and glaucoma - a leading cause of irreversible blindness for which current treatments reduce intraocular pressure but do not prevent degeneration of the optic nerve. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.

 

END